Evidence map›Paper›PMID 39910913›Full record

ArticleCancer medicine2025

Impact of Multimorbidity on Symptom Burden and Symptom Clusters in Patients Receiving Chemotherapy.

Carolyn Harris, Marilyn J Hammer, Yvette P Conley, Steven M Paul, Bruce A Cooper, Joosun Shin, Kate Oppegaard, Lisa Morse, Jon D Levine, Christine Miaskowski

Abstract read
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Association of patient factors and health-related quality of life with weight changes during chemotherapy for colorectal cancer: secondary analysis of the SCOT trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Trial
  2. Symptom clusters and network analysis in lung cancer patients receiving taxane-based chemotherapy: a comprehensive assessment using the CIPNAT multi-scale tool.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Carolyn HarrisSchool of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Marilyn J HammerDana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-9561-6144
Yvette P ConleySchool of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Steven M PaulSchool of Nursing, University of California, San Francisco, California, USA.
Bruce A CooperSchool of Nursing, University of California, San Francisco, California, USA.
Joosun ShinDana-Farber Cancer Institute, Boston, Massachusetts, USA.
Kate OppegaardVA Portland Health Care System, Portland, Oregon, USA.
Lisa MorseSchool of Nursing, University of California, San Francisco, California, USA.
Jon D LevineSchool of Medicine, University of California, San Francisco, California, USA.
Christine MiaskowskiSchool of Nursing, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-5170-2027

Funding

Symptoms Clusters in Oncology Patients Receiving ChemotherapyR01CA134900 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, MIASKOWSKI, CHRISTINE A. · 2009 to 2014
$5.9M
Characterization of the Symptom Experience of Patients with Cutaneous Melanoma Receiving Immune Checkpoint Inhibitor TherapyR00CA286967 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Carolyn Stigge Harris · 2025 to 2026
$402k
Influence of Social Determinants of Health and Epigenomics on Psychological Symptom Cluster SeverityK99CA286967 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HARRIS, CAROLYN STIGGE · 2024 to 2025
$323k
National Cancer Institute US CA134900National Cancer Institute US CA286967NCI NIH HHS K99 CA286967NCI NIH HHS R00 CA286967NCI NIH HHS R01 CA134900
6 · The paper itself

Abstract

backgroundDetailed information on patient characteristics and symptom burden associated with multimorbidity in oncology patients is extremely limited. Purposes were to determine the prevalence of low (≤ 2) and high (≥ 3) multimorbidity in a sample of oncology outpatients (n = 1343) undergoing chemotherapy and evaluate for differences between the two multimorbidity groups in demographic and clinical characteristics; the occurrence, severity, and distress of 38 symptoms; and the stability and consistency of symptom clusters.

methodsUsing the Self-Administered Comorbidity Questionnaire, patients were classified into low and high multimorbidity groups. Memorial Symptom Assessment Scale was used to assess the occurrence, severity, and distress of 38 symptoms prior to the patients' second or third cycle of chemotherapy. For each multimorbidity group, symptom clusters based on occurrence rates were identified using exploratory factor analysis.

resultsCompared to the low group (61.4%), patients in the high group (38.6%) were older, had fewer years of education, were less likely to be married or partnered, less likely to be employed, and had a lower annual income. In addition, they had a higher body mass index, poorer functional status, were a longer time since their cancer diagnosis, and were more likely to have received previous cancer treatments and have metastatic disease. Patients in the low and high groups reported 12.7 (±6.7) and 15.9 (±7.5) concurrent symptoms, respectively. Eight and seven symptom clusters were identified for the low and high groups, respectively. Psychological, gastrointestinal, weight gain, hormonal, and respiratory clusters were stable across multimorbidity groups. Weight gain and respiratory clusters were consistent. Three unstable clusters were identified in the low group and two in the high group.

conclusionsFindings suggest that higher multimorbidity is associated with various social determinants of health and a higher symptom burden. Differences between multimorbidity groups may be related to aging, treatments, and/or comorbid conditions.

Indexed as

MultimorbidityNeoplasmsAdultAgedComorbidityCost of IllnessFemaleHumansMaleMiddle AgedPrevalenceSeverity of Illness IndexSurveys and QuestionnairesSymptom AssessmentSymptom Burdencancerchemotherapyclustersmultimorbiditysocial determinants of healthsymptoms

Identifiers

PMID39910913
PMCPMC11799588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.